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OBJECTIVE: Circulating microRNAs have been recognized as promising biomarkers for various diseases. The
present study aimed to explore the potential roles of circulating miR-149, miR-424 and miR-765 as non-invasive
biomarkers for the diagnosis of coronary artery disease in middle-aged (40–60-year-old) patients.
METHODS: Sixty-five stable coronary artery disease patients (49–57 years old), 30 unstable coronary artery disease
patients (49–58 years old), and 32 non-coronary artery disease patients (49–-57 years old) who were matched for age,
sex, smoking habits, hypertension and diabetes were enrolled in this study. Total RNAwas isolated from plasma with
TRIzol reagent. Circulating miRNA levels were measured by quantitative real-time polymerase chain reaction.
RESULTS: Circulating miR-149 levels were decreased 4.49-fold in stable coronary artery disease patients (1.18± 0.84)
and 5.09-fold in unstable coronary artery disease patients (1.04± 0.65) compared with non-coronary artery disease
patients (5.30± 2.57) (po0.001). Circulating miR-424 levels were reduced 3.6-fold in stable coronary artery disease
patients (1.18 ± 0.60) and 5-fold in unstable coronary artery disease patients (0.86 ± 0.54) compared with
non-coronary artery disease patients (4.35 ± 2.20) (po0.001). In contrast, circulating miR-765 levels were elevated
3.98-fold in stable coronary artery disease patients (6.09 ± 2.27) and 5.33-fold in unstable coronary artery disease
patients (8.17 ± 2.77) compared with non-coronary artery disease patients (1.53 ± 0.99) (po0.001). Receiver
operating characteristic curve analysis revealed that the respective areas under the curve for circulating miR-149,
miR-424 and miR-765 were 0.938, 0.919 and 0.968 in stable CAD patients and 0.951, 0.960 and 0.977 in unstable
coronary artery disease patients compared with non-coronary artery disease patients.
CONCLUSION: Our results suggest that circulating miR-149, miR-424 and miR-765 might be novel, non-invasive
biomarkers for the diagnosis of coronary artery disease in middle-aged patients. However, future prospective
trials in large patient cohorts are necessary before reaching a solid conclusion.
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’ INTRODUCTION
Coronary artery disease (CAD) remains the leading cause
of sudden cardiac death (SCD) in the world and a major
cause of hospital admissions (1). The total CAD prevalence is
6.4% in US adults over 20 years of age. Among Asians over 18
years of age, the estimated incidence of CAD is 4.3%, and the
prevalence of CAD will increase approximately 18% by 2030
(2). CAD is caused by the build-up of atherosclerotic plaque
along the tunica intima walls of the coronary arteries of the
heart, which narrows the coronary arteries and reduces blood
flow to the heart. An early and correct diagnosis of CAD is
important for the prevention of heart attacks and SCD. CAD is
hard to diagnose without the help of the well-established
invasive coronary angiogram (CAG) technique. Although ECG
and ETT have been widely used, there is no specific plasmaDOI: 10.6061/clinics/2015(04)07
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biomarker for the clinical diagnosis of CAD, particularly for the
early diagnosis of CAD. Therefore, there is a clinical demand
for specific and reliable non-invasive biomarkers for the early
diagnosis of CAD.
Circulating microRNAs (miRNAs) have attracted major
interest as novel biomarkers for the early diagnosis of CAD
(3). miRNAs are a class of small (B22 nucleotides long),
highly specific, endogenous, single-stranded, non-coding
RNAs that regulate the expression of target genes by binding
to the 39 untranslated region and degrading or inhibiting the
translation of mRNAs (4). It is well established that miRNAs
play critical roles in physiological and pathological processes
in the cardiovascular system, such as endothelial dysfunc-
tion, inflammation, apoptosis, angiogenesis, atherosclerosis,
and neointimal hyperplasia or restenosis (5–8).
miRNAs in plasma or serum, called circulating miRNAs,
exhibit remarkable stability and are highly resistant to
plasma RNase activity due to internalization in microvesicles
and the formation of protein–miRNA complexes (9–12).
Therefore, the levels of individual cardiac-enriched circulat-
ing miRNAs are related to the diagnosis and prognosis of
heart diseases (13). Recently, it has been demonstrated that
the expression levels of circulating miRNAs are significantly
altered in patients with unstable angina, acute coronary
syndrome, acute myocardial infarction (AMI), heart failure,
atrial fibrillation, stroke and cancer (14–21). Recently, certain
circulating miRNAs, such as miR-208b, miR-499, miR-1,
miR-126, miR-133, miR-1291 and miR-663b, have been
recognized as novel potential biomarkers for the diagnosis
of AMI (22–24). The levels of circulating miR-423-5p, miR-
103, miR-142-3p, miR-30b and miR-342-3p were highly
correlated with heart failure (25,26). Circulating miR-135a
and miR-31 levels are up-regulated, whereas miR-378 and
miR-147 levels are down-regulated in patients with stable
CAD compared with healthy subjects (12). However, there
have been no reports regarding circulating miRNAs as non-
invasive biomarkers for the diagnosis of CAD in middle-aged
patients. In this study, we detected the plasma levels of
miR-149, miR-424 and miR-765 in middle-aged (40–60 years
old) CAD patients to explore their potential role as biomarkers
for the diagnosis of CAD in middle-aged patients.
’ MATERIALS AND METHODS
Study subjects
Thirty-two non-CAD patients, sixty-five consecutive CAD
patients and thirty unstable angina (UA) patients admitted to
Xiangya Hospital, Central South University, Hunan, China,
from March 2012 to December 2013 were enrolled in this
study. The diagnosis of CAD was confirmed by coronary
angiogram. CAD was defined as at least one major coronary
artery with Z50% stenosis based on a modified form of the
AHA/ACC classification of the coronary tree. CAD was
defined as either stable or unstable according to ACC/AHA
guidelines (27,28). The exclusion criteria for CAD patients
were as follows: previous history of AMI; elevated cardiac
troponin I (cTnI) or creatine kinase (CK-MB) levels; impaired
left ventricular ejection fraction (LVEF) (r45%); congestive
heart failure; cardiac arrhythmias and pacing; severe hepatic
and renal dysfunction; renal replacement therapy; chronic
inflammatory and malignant disease; age over 60 years;
and any major operation within the previous month. The
non-CAD patients were matched for age, sex, smoking
habits, hypertension and diabetes, and CAD and other
diseases of interest were excluded based on the following
criteria: 12-lead ECG, ETT and echocardiogram reports
within normal limits; no history of stroke; no history of
acute or chronic hepatic or renal disease; and no hospitaliza-
tions for at least 1 month prior to participation. The study
was approved by the Local Medical Ethics Committee of
Xiangya Hospital, Central South University, Hunan, China,
and the protocol was performed according to the principles
of the Declaration of Helsinki (2008) of the World Medical
Association. All the participants provided written informed
consent at the time of enrollment.
Sample collection
Peripheral 5 ml blood samples were obtained in K2-EDTA-
coated tubes from the antecubital veins of CAD and non-
CAD patients and were processed within 30 min of collection
using two-step centrifugation. Samples were first centrifuged
at 1,500  g for 15 min at 4˚C. The supernatant was collected
and then centrifuged again at 14,000  g for 15 min at 4˚C to
obtain pure plasma. Finally, the plasma was transferred to
RNase-free tubes and stored at -80˚C.
RNA isolation from plasma
Total RNA was extracted using a TRIzol-based miRNA
isolation protocol (Invitrogen, Carlsbad, CA, USA) (1). We
added 750 ml of TRIzol reagent to 250 ml of plasma, and the
resulting solution was mixed well and incubated at room
temperature (RT) for 5 min prior to the addition of 200 ml of
chloroform and a 3-min incubation at RT. The three phases
(aqueous, inter, and organic) were obtained by centrifugation at
4˚C and 12,000 rpm for 15 min. (2). The upper aqueous phase
was collected, mixed with 500 ml of 100% isopropanol and
incubated at -20˚C overnight; then, the samples were centri-
fuged at 4˚C and 13,000 rpm for 15 min to enable RNA
precipitation. RNA samples were cleaned twice with 80%
ethanol (500 ml) and centrifuged again at 4˚C and 7500 rpm for
10 min (3). The supernatants were removed, and the precipitates
were dried at RT for 5 min. Subsequently, the RNA samples
were diluted in 30 ml of RNase-free water and incubated at 4˚C
for 8 hours. Finally, the RNA concentrations of 2 ml aliquots
were measured with a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Inc. Wilmington, USA), and the RNA
samples were stored at  80˚C for future use.
Detection and analysis of miRNAs by qRT-PCR
We used real-time quantitative reverse-transcription poly-
merase chain reaction (qRT-PCR) to determine the expression
of miRNAs. First, 4 mL of pure RNA (OD 1.8-2.2) was
reverse-transcribed (RT) to cDNA at 42˚C for 30 min
using miRNA-specific reverse transcription kits (RiboBio,
Guangzhou, China) according to the manufacturer's instruc-
tions with an RT-PCR system (Bio-Rad, USA). Second, 2 mL
of cDNA was used as the template for qRT-PCR. Plasma
miR-149, miR-424 and miR-765 expression was detected
using SYBR Green miRNA qRT-PCR kits (Takara, Dalian,
China) according to the manufacturer's protocol and a 7300
Real-Time PCR System (Applied Biosystems, CA, USA). A
melting curve analysis was performed at the end of the PCR
cycle to validate the specificity of the expected PCR product.
We used miR-156a as an internal control due to its persistent
and stable expression throughout all the evaluated samples.
Each sample from each study subject was analyzed by PCR
in triplicate. The relative expression level of each miRNAwas
computed using the comparative CT method, which was
258
Circulating miRNAs and coronary artery disease
Md Sayed AS et al.
CLINICS 2015;70(4):257-263
defined as 2DCt, where DCt = (Ct miRNA of sample x  Ct
miR-156a of sample x). The samples with qRT-PCR Ct values
greater than 40 were considered not expressed. To reduce the
number of false positives, we only measured miRNAs whose
expression in CAD and unstable patients differed from the
healthy controls by more than 2-fold on average.
Biochemical and clinical assays
Fasting blood sugar (FBS), triglycerides (TG), total cholesterol
(TC), low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and high-sensitivity
C-reactive protein (hs-CRP) were measured using an automatic
analyzer (Hitach75, Tokyo, Japan). Clinical history, family
history, drug history, physical examination, serial 12-lead
ECG and echocardiogram reports were recorded.
Statistical analysis
Data were analyzed with SPSS software (version 20.0,
SPSS, Chicago, IL) and reported as the mean ± standard
deviation (SD). Differences among groups were compared
using Student’s t-test and one-way ANOVA; for categorical
variables, Fischer's exact test or the Chi-Square (w2) test was
used, and for non-Gaussian distributions, rank transforma-
tion and the Wilcoxon test were used. The miRNA
expression data were used to generate graphs with Graph-
Pad Prism version 6 for Windows (GraphPad Software,
San Diego, CA, USA) and were presented as the mean ±
standard error (SEM). ROC analysis was used to assess the
diagnostic accuracy of each circulating miRNA for all the
groups. The area under the ROC curve (AUC) was
considered a diagnostic index, and the best cut-off point
was obtained based on the highest sensitivity and specificity
values. All the tests were 2-sided, and differences with
po0.05 were considered to be statistically significant.
’ RESULTS
Clinical participant information
We enrolled a total of 95 CAD patients, including 65 with
stable CAD (49–57 years old) and 30 with unstable CAD
(49–58 years old), and 32 non-CAD patients (49–57 years old)
who were matched for age, sex, hypertension and diabetes.
Body mass index, diabetes mellitus, systolic blood pressure,
diastolic blood pressure, LVEF, FBS, TC, TG, HDL-C, LDL-C, hs-
CRP, AST, ALT, creatinine, smoking habits, hypertension and
treatment records were collected. Clinical and laboratory
characteristics of the participants are presented in Tables 1 and 2.
The expression levels of circulating miRNAs in CAD
versus non-CAD patients
We analyzed the plasma expression levels of miR-149,
miR-424 and miR-765 in stable CAD, unstable CAD and non-
CAD patients. The results are presented in Figure 1. The
Table 1 - Clinical data from the study subjects.
Variable Non-CAD patients (n = 32) CAD patients (n = 65) UA patients (n = 30) p1 p2
Age (years) 53 (49–57) 53 (49–57) 54 (49–58) 0.957 0.471
Male/Female 16/16 38/27 20/12 0.516 0.208
BMI (kg/m2) 22 (20–23) 22 (19–25) 23 (20–27) 0.706 0.124
Active Smoker (%) 59.37 63.07 67 0.825 0.606
Hypertension (%) 56.25 70.76 73.3 0.177 0.192
Dyslipidemia (%) 37.50 41.53 43.33 0.826 0.796
DM (%) 15.63 20 23.33 0.783 0.529
SBP (mmHg) 127 (119–135) 131 (117–146) 134 (122–146) 0.330 0.018
DBP (mmHg) 79 (72–86) 80 (73–86) 82 (75–90) 0.587 0.076
LVEF (%) 66 (60–72) 63 (55–71) 62 (53–70) 0.238 0.075
Medications
Aspirin (%) 34.3 53.84 60 0.086 0.074
b-blocker (%) 40.62 61.53 66.66 0.082 0.047
CCB (%) 31.25 38.46 46.66 0.511 0.298
ACEI/ARB (%) 28.12 35.84 40 0.502 0.423
Statin (%) 46.87 61.53 63.33 0.196 0.213
Diuretic (%) 18.75 24.61 26.66 0.612 0.550
The data are presented as the median and range. Abbreviations: UA, unstable angina; BMI, body mass index; DM, diabetes mellitus; SBP, systolic blood
pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme
inhibitor; and ARB, angiotensin receptor blocker. p1-value (non-CAD patients vs. CAD patients), p2-value (non-CAD patients vs. UA patients).
Table 2 - Laboratory data from the study subjects.
Variable Non-CAD patients (n = 32) CAD patients (n = 65) UA patients (n = 30) p1 p2
FBS (mmol/L) 4.9 (4.3–5.4) 5.1 (4.2–6.1) 5.2 (3.9–6.7) 0.234 0.490
TG (mmol/L) 1.5 (0.5–2.5) 1.6 (0.6–2.7) 1.8 (0.8–2.7) 0.454 0.126
TC (mmol/L) 4.4 (2.9–5.9) 4.9 (3.3–6.5) 5.3 (3.7-7) 0.177 0.038
HDL-C (mmol/L) 0.9 (0.5–1.4) 0.9 (0.4–1.4) 0.9 (0.5–1.3) 0.595 0.746
LDL-C (mmol/L) 2.7 (1.5–3.8) 2.9 (1.4–4.4) 3.2 (2.1–4.3) 0.872 0.024
hs-CRP (mg/L) 1.4 (0.5–2.7) 19.8 (9.9–29.5) 21.3 (15–27.5) o0.001 o0.001
AST (U/L) 15.3 (6.9–24) 17.7 (8.3–27.1) 19.8 (12.6–27) 0.294 0.019
ALT (U/L) 17.1 (9.1–25) 19.1 (10.7–27.4) 21.5 (13.4–29.6) 0.244 0.042
Cr (umol/L) 71.5 (52.4–90) 74.8 (53.4–96.1) 79.8 (58.6–101.1) 0.602 0.049
The data are presented as the median and range. Abbreviations: FBS, fasting blood sugar; TC, total cholesterol; TG, triglycerides; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; and Cr, creatinine. p1-value (CAD patients vs. non-CAD patients), p2-value (UA patients vs. non-CAD patients).
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levels of plasma miR-149 in stable CAD and unstable CAD
patients were 4.49-fold (1.18 ± 0.84) and 5.09-fold (1.04 ±
0.65) lower, respectively, than those in non-CAD patients
(5.30 ± 2.57) (po0.001). Circulating miR-424 levels were
down-regulated 3.6-fold (1.18± 0.60) in stable CAD patients
and 5-fold (0.86± 0.54) in unstable CAD patients compared
with those in non-CAD patients (4.35 ± 2.20) (po0.001). In
contrast, the plasma concentrations of miR-765 were elevated
3.98-fold (6.09 ± 2.27) in stable CAD patients and 5.33-fold
(8.17± 2.77) in unstable CAD patients compared with those
in non-CAD patients (1.53 ± 0.99). The plasma levels of
miR-149 and miR-424 were not significantly different
between stable and unstable CAD patients, whereas the
plasma levels of miR-765 were significantly different
between stable and unstable CAD patients (po0.001).
Diagnostic role of plasma miRNAs in middle-aged
CAD patients
To examine the potential of miRNAs (miR-149, miR-424, and
miR-765) as biomarkers for middle-aged CAD patients, ROC
analysis was performed on all 127 subjects. The ROC curves of
plasma miR-149 revealed a strong discrimination between
non-CAD patients, stable CAD patients and unstable CAD
patients, with AUCs of 0.938, 0.951 and 0.539, respectively
(Figure 2A, 2B, and 2C). The ROC curves of plasma miR-424
revealed significant differences between non-CAD patients,
CAD patients and unstable CAD patients, with AUCs of 0.919,
0.960 and 0.682, respectively (Figure 2D, 2E, and 2F).
Furthermore, the ROC curves of plasma miR-765 also
accurately differentiated stable and unstable CAD patients
from non-CAD patients, with AUCs of 0.968, 0.977 and 0.760,
respectively (Figure 2G, 2H, and 2I). These results indicated
that plasma miR-149, miR-424 and miR-765 might be valuable
biomarkers for middle-aged CAD patients. The AUCs, max-
imum cut-off points, sensitivities, specificities, 95% CIs (con-
fidence intervals) and p-values of the circulatory miRNAs (miR-
149, miR-424, and miR-765) are briefly summarized in Table 3.
’ DISCUSSION
CAD is the most important cause of heart attacks and
resulted in 3.6 million deaths in the year of 1990 in
developing countries; this number will approximately
increase to 7.8 million deaths by the year 2020 (29). The
main cause of CAD is atherosclerosis, which is a hyperlipi-
demia-induced chronic inflammatory disease of the arterial
wall that occurs predominantly at sites of disturbed laminar
blood flow due to endothelial dysfunction. Emerging
evidence suggests that alterations in flow conditions regulate
the expression of miRNAs in endothelial cells both in vitro and
in vivo (30). The administration of miR-126-5p rescued EC
proliferation at predilection sites and limited atherosclerosis by
suppressing the Notch1 inhibitor delta-like 1 homolog (Dlk1),
introducing a potential therapeutic approach (31). miR-33 has
Figure 1 - Plasma expression levels of miR-149, miR-424 and miR-765 in non-CAD patients, stable CAD patients and unstable CAD
patients.
Table 3 - Receiver operator characteristic curve (ROC) analysis of miRNA ratios for predicting coronary artery disease.
miRNA AUC Cut-off point Sensitivity Specificity 95% CI p-value
miR-149
Non-CAD vs. CAD 0.938 1.67 71.8% 95.3% 0.894 to 0.983 o0.0001
Non-CAD vs. UA 0.951 1.71 75% 96.6% 0.905 to 0.997 o0.0001
CAD vs. UA 0.539 1.15 75% 40% 0.415 to 0.663 0.540
miR-424
Non-CAD vs. CAD 0.919 1.61 68.7% 92.3% 0.863 to 0.975 o0.0001
Non-CAD vs. UA 0.960 1.77 84.3% 93.3% 0.920 to 1.000 o0.0001
CAD vs. UA 0.682 1.35 89.2% 46.6% 0.559 to 0.805 0.005
miR-765
Non-CAD vs. CAD 0.968 1.75 81.5% 93.7% 0.939 to 996 o0.0001
Non-CAD vs. UA 0.977 1.80 83.3% 96.8% 0.949 to 1.005 o0.0001
CAD vs. UA 0.760 1.57 66.5% 90.7% 0.635 to 0.885 o0.0001
AUC, area under the curve; CAD, coronary artery disease; Non-CAD, non-coronary artery disease; UA, unstable angina (unstable coronary artery disease);
95% CI, confidence interval.
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been discovered as a key regulator of the initiation and
progression of atherosclerosis by controlling lipid metabolism,
the inflammatory response and cell cycle progression and
proliferation (32). miR-1 prevents high-cholesterol-induced
endothelial dysfunction through myosin light chain kinase
(MLCK) expression and extracellular signal-regulated kinase
(ERK) phosphorylation (33). Monocytes migrate from the
circulation into the intima by binding to activated endothelial
cells and later differentiate into macrophages. miR-424 promotes
monocyte/macrophage differentiation and is intimately
involved in the initiation and progression of atherosclerotic
lesions and the development of associated complications.
Ezetimibe (a lipid-lowering agent) decreased the expression of
miR-424 by 75% and decreased atherosclerotic lesions (34).
In addition, several miRNAs are directly and indirectly
involved in the pathophysiological mechanisms of athero-
sclerosis, such as miR-19a, miR-21, miR-23b, miR-92a, miR-
143, miR-145, miR-155, miR-663 and miR-133a (30,35).
Although enormous progress has been made in the
diagnosis, treatment and prognosis of CAD, there remains
a clinical need for a novel diagnostic biomarker and new
therapeutic interventions to decrease the incidence of CAD.
Biomarkers play an essential role in the diagnosis of CAD.
However, many of these biomarkers have shortcomings,
such as reduced sensitivity, low specificity or unsuitability
for early diagnosis. However, several recent studies have
suggested that circulating miRNAs are excellent promising
biomarkers for the early diagnosis of AMI (18,23–25,36).
Figure 2 - Diagnostic accuracy of circulating miR-149, miR-424 and miR-765 were analyzed by ROC curve. A) ROC curve of miR-149, non-
CAD patients vs. CAD. B) ROC curve of miR-149, non-CAD patients vs. unstable CAD patients. C) ROC curve of miR-149,
CAD vs. unstable CAD patients. D) ROC curve of miR-424, non-CAD patients vs. CAD. E) ROC curve of miR-424, non-CAD patients vs.
unstable CAD patients. F) ROC curve of miR-424, CAD vs. unstable CAD patients. G) ROC curve of miR-765, non-CAD patients vs. CAD. H)
ROC curve of miR-765, non-CAD patients vs. unstable CAD patients. I) ROC curve of miR-765, CAD vs. unstable CAD patients.
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Circulating levels of miR-133a, miR-208a, miR-1, miR-122,
miR-133b, miR-337-5p, miR-433, and miR-485-3p were
significantly up-regulated, whereas miR-126, miR-17, miR-
92a, miR-145, miR-155, and miR-199a levels were markedly
down-regulated in CAD (14,37).
Circulating miRNA levels in middle-aged CAD patients
have not yet been investigated. We specifically focused on
middle-aged people for the following reasons: one, they are the
most active contributors to the development of society; and
two, although the invasive CAG procedure is the standard
method for diagnosing CAD, it has many complications. The
present work demonstrated that circulating miRNAs might be
clinically feasible biomarkers for diagnosing middle-aged CAD
patients. We discovered that plasma miR-149 and miR-424
levels were significantly down-regulated, whereas plasma miR-
765 levels were up-regulated in stable and unstable CAD
patients compared with non-CAD patients. In addition, we
measured the diagnostic value of plasma miR-149, miR-424
and miR-765 levels using ROC curves. The AUC values for
miR-149, miR-424 and miR-765 were significantly higher in
stable CAD patients (0.938, 0.919 and 0.968, respectively) and
unstable CAD patients (0.951, 0.960 and 0.977, respectively)
compared with non-CAD patients. These results strongly
indicated that plasma miR-149, miR-424 and miR-765 might
be valuable novel non-invasive biomarkers for the early
diagnosis of middle-aged CAD patients.
Recent studies have revealed that 5,10-methylenetetrahy-
drofolate reductase (MTHFR) plays a critical role in homo-
cysteine metabolism. The abnormal function of MTHFR
increases plasma homocysteine levels to enhance endothelial
dysfunction and atherosclerosis. The human MTHFR
rs4846049 (T-allele) polymorphism was significantly asso-
ciated with an increased risk of CAD and dyslipidemia via
modification of the binding of miR-149 in a Chinese Han
population (38). Furthermore, the miR-149T4C polymorph-
ism was significantly associated with ischemic stroke and
silent brain infarction (SBI) risk in a Korean population (39).
TNF-a plays an essential role in the initiation and progression
of endothelial dysfunction. The transfection of miR-149
mimics counteracted the TNF-a-induced expression of metal-
loproteinase-9 (MMP-9), inducible nitric oxide synthase
(iNOS), and interleukin-6 (IL-6) and regulated TNF-a-induced
endothelial dysfunction (40). miR-149 expression was sig-
nificantly down-regulated in infarcted mouse hearts three
days after MI and in cardiac tissue from the border zone of the
infarcted region in patients receiving a cardiac transplant (41).
In our study, circulating miR-424 levels were significantly
decreased in CAD patients, which is consistent with studies
from Fichtlscherer et al (14). Moreover, plasma miR-424
levels were significantly down-regulated in acute ischemic
stroke patients as well as in mouse plasma and brain tissue 4
hours after ischemia. In addition, overexpressing miR-424
mimics decreased the ischemic brain injury by suppressing
microglia activation via the translational depression of key
activators of the G1/S transition, including CDC25A,
CCND1, and CDK6 (42). miR-424 levels were also signifi-
cantly decreased in pulmonary arterial hypertension (PAH)
due to the dysregulation of the apelin (APLN) and fibroblast
growth factor 2 (FGF2) signaling pathways (43). The specific
target of miR-424 in cardiac cells is currently unknown and
awaits elucidation in future studies.
Redell JB et al. (44) reported that plasma miR-765 levels
were markedly increased in traumatic brain injury (TBI)
patients compared with healthy volunteers. ROC curve
analysis indicated that miR-765 was a good biomarker,
especially for severe TBI. However, the exact mechanisms for
the altered expression of miR-765 in CAD remain unknown.
Using target scan (www.targetscan.org), hsa-miR-765 was
predicted to potentially be involved in CAD by regulating
several important target genes, such as HIF3A (hypoxia
inducible factor-3, a subunit), NADPH oxidase, low density
lipoprotein receptor-related protein 4 (LRP4), and low
density lipoprotein receptor-related protein 6 (LRP6).
To ensure that the study populations were comparable,
subjects with similar clinical features, such as age, gender, TC,
TG, HDL-C, LDL-C, systolic blood pressure, diastolic blood
pressure, AST, ALT, creatinine, LVEF, diabetes mellitus, smoking,
hypertension and medication history, were carefully considered.
Statistical analyses revealed that these factors did not affect
circulating miR-149, miR-424 and miR-765 levels. Importantly,
three plasma miRNAs (miR-149, miR-424 and miR-765)
displayed a direct relationship in stroke patients, but we
excluded stroke patients in our study to minimize possible bias.
To decrease potential errors resulting from qRT-PCR assays,
we evaluated three potential internal controls (U6, miR-cel-39,
and miR-156a) in a pre-analysis (n = 20). We ultimately chose
miR-156a for standard normalization because it was more stable
and reliable (36). We analyzed each sample in triplicate, and
miRNAs with Ct values Z40 were not included in our study,
which assured that our results were constant and reproducible.
To the best of our knowledge, the present study is the first to
demonstrate that plasma miR-149, miR-424 and miR-765 might
be non-invasive novel biomarkers for middle-aged CAD
patients. However, there are several limitations that need to
be acknowledged and addressed regarding the present study.
First, this work was performed in a single center with a small
cohort. Therefore, a multi-center study with a larger cohort is
necessary to verify the findings of this present study. Second,
the specificity of the changes in the three measured miRNAs in
middle-aged CAD patients remains unclear because we did not
measure these miRNAs in other age groups of CAD patients or
in other clinical settings. Third, we did not include healthy
subjects as normal controls.
In conclusion, our findings suggest that circulating miR-
149, miR-424 and miR-765 might be non-invasive biomarkers
for the diagnosis of CAD in middle-aged patients. However,
the sensitivity and specificity of these miRNAs need to be
further examined in a larger clinical cohort.
’ ACKNOWLEDGMENTS
This work was supported by the National Nature Science Foundation of
China (No. 81370320 to Tian-Lun Yang and No. 81373409 to Jun Peng),
the Hunan Provincial Natural Science Foundation of China (No. 13JJ2008
to Peng J.) and the Doctoral Fund of Ministry of Education of China (No.
20120162110056 to Peng J.)
’ AUTHOR CONTRIBUTIONS
Sayed AS and Xia K designed the research, performed the experiments and
wrote the manuscript. Deng X, Deng H, Yangda F, Li F, Haoyang Z, Li T,
and Salma U collected patient samples and assembled the data. Yang T and
Peng J supervised the data analysis and revised the manuscript. The work
presented in this paper was performed in collaboration with all the authors.
’ REFERENCES
1. Braza-Boils A, Mari-Alexandre J, Molina P, Domingo D, Abellan Y, Sancho
J, et al. P62Role of microRNAs associated with non-alcoholic fatty liver
262
Circulating miRNAs and coronary artery disease
Md Sayed AS et al.
CLINICS 2015;70(4):257-263
disease in sudden cardiac death from coronary artery disease. Cardiovasc
Res. 2014;103(Suppl 1):S10.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al.
Heart disease and stroke statistics--2014 update: a report from the
American Heart Association. Circulation. 2014;129(3):e28-292, http://dx.
doi.org/10.1161/01.cir.0000441139.02102.80.
3. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and
potential paracrinemediators of cardiovascular disease. Circ Cardiovasc Genet.
2010;3(5):484-8, http://dx.doi.org/10.1161/CIRCGENETICS.110.958363.
4. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, et al. Micro-
particles: major transport vehicles for distinct microRNAs in circulation.
Cardiovasc Res. 2012;93(4):633-44, http://dx.doi.org/10.1093/cvr/cvs007.
5. Peng Y, Song L, Zhao M, Harmelink C, Debenedittis P, Cui X, et al. Critical
roles of miRNA-mediated regulation of TGFb signalling during mouse
cardiogenesis. Cardiovasc Res. 2014;103(2):258-67, http://dx.doi.org/
10.1093/cvr/cvu126.
6. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biol-
ogy. Nature. 2011;469(7330):336-42, http://dx.doi.org/10.1038/nature09783.
7. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in car-
diac development and disease. Cardiovasc Res. 2008;79(4):562-70, http://
dx.doi.org/10.1093/cvr/cvn137.
8. Dangwal S, Bang C, Thum T. Novel techniques and targets in cardio-
vascular microRNA research. Cardiovasc Res. 2012;93(4):545-54, http://
dx.doi.org/10.1093/cvr/cvr297.
9. Mar-Aguilar F, Rodríguez-Padilla C, Reséndez-Pérez D. Use of serum-
circulating miRNA profiling for the identification of breast cancer bio-
markers. Methods Mol Biol. 2014;1165:71-80, http://dx.doi.org/10.1007/
978-1-4939-0856-1.
10. Gidlöf O, Andersson P, van der Pals J, Götberg M, Erlinge D. Cardiospecific
microRNA plasma levels correlate with troponin and cardiac function in
patients with ST elevation myocardial infarction, are selectively dependent
on renal elimination, and can be detected in urine samples. Cardiology.
2011;118(4):217-26, http://dx.doi.org/10.1159/000328869.
11. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al.
Argonaute2 complexes carry a population of circulating microRNAs
independent of vesicles in human plasma. Proc Natl Acad Sci U S A.
2011;108(12):5003-8, http://dx.doi.org/10.1073/pnas.1019055108.
12. Sayed AS, Xia K, Salma U, Yang T, Peng J. Diagnosis, Prognosis and
Therapeutic Role of Circulating miRNAs in Cardiovascular Diseases. Heart
Lung Circ. 2014;23(6):503-10, http://dx.doi.org/10.1016/j.hlc.2014.01.001.
13. Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to
cardiovascular disease. Circulation. 2010;121(8):1022-32, http://dx.doi.
org/10.1161/CIRCULATIONAHA.109.889048.
14. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al.
Circulating microRNAs in patients with coronary artery disease. Circ Res.
2010;107(5):677-84, http://dx.doi.org/10.1161/CIRCRESAHA.109.215566.
15. Zeller T, Keller T, Ojeda F, Reichlin T, Twerenbold R, Tzikas S, et al.
Assessment of microRNAs in patients with unstable angina pectoris. Eur
Heart J. 2014;35(31):2106-14, http://dx.doi.org/10.1093/eurheartj/ehu151.
16. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K,
et al. Diagnostic and prognostic impact of six circulating microRNAs in
acute coronary syndrome. J Mol Cell Cardiol. 2011;51(5):872-5, http://dx.
doi.org/10.1016/j.yjmcc.2011.07.011.
17. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA:
a novel potential biomarker for early diagnosis of acute myocardial
infarction in humans. Eur Heart J. 2010;31(6):659-66, http://dx.doi.org/
10.1093/eurheartj/ehq013.
18. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of
microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14(2):147-54,
http://dx.doi.org/10.1093/eurjhf/hfr155.
19. McManus DD, Lin H, Tanriverdi K, Quercio M, Yin X, Larson MG, et al.
Relations between circulating microRNAs and atrial fibrillation: data from
the Framingham Offspring Study. Heart Rhythm. 2014;11(4):663-9,
http://dx.doi.org/10.1016/j.hrthm.2014.01.018.
20. Tsai PC, Liao YC, Wang YS, Lin HF, Lin RT, Juo SH. Serum microRNA-21
and microRNA-221 as Potential Biomarkers for Cerebrovascular Disease
J Vasc Res. 2013;50(4):346-54, http://dx.doi.org/10.1159/000351767.
21. Waters PS, Dwyer RM, Brougham C, Glynn CL, Wall D, Hyland P, et al.
Impact of tumour epithelial subtype on circulating microRNAs in breast
cancer patients. PLoS One. 2014;9(3):e90605, http://dx.doi.org/10.1371/
journal.pone.0090605.
22. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al.
Circulating microRNA-208b and microRNA-499 reflectmyocardial damage
in cardiovascular disease. Circ Cardiovasc Genet. 2010;3(6):499-506, http://
dx.doi.org/10.1161/CIRCGENETICS.110.957415.
23. Long G, Wang F, Duan Q, Chen F, Yang S, Gong W, et al. Human circu-
lating microRNA-1 and microRNA-126 as potential novel indicators for
acute myocardial infarction. Int J Biol Sci. 2012;8(6):811-8, http://dx.doi.
org/10.7150/ijbs.4439.
24. Peng L, Chun-guang Q, Bei-fang L, Xue-zhi D, Zi-hao W, Yun-fu L, et al.
Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma
of patients with acute myocardial infarction. Diagn Pathol. 2014;1(9):89,
http://dx.doi.org/10.1186/1746-1596-9-89.
25. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok
WE, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res.
2010;106(6):1035-9, http://dx.doi.org/10.1161/CIRCRESAHA.110.218297.
26. Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, Richards
AM. Circulating microRNAs as candidate markers to distinguish heart fail-
ure in breathless patients. Eur J Heart Fail. 2013;15(10):1138-47, http://dx.
doi.org/10.1093/eurjhf/hft078.
27. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al.
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the
diagnosis and management of patients with stable ischemic heart disease: a
report of the American College of Cardiology Foundation/ American Heart
Association Task Force on Practice Guidelines, and the American College of
Physicians, American Association for Thoracic Surgery, Preventive Cardi-
ovascular Nurses Association, Society for Cardiovascular Angiography and
Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60
(24):e44-??e164, http://dx.doi.org/10.1016/j.jacc.2012.07.013.
28. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman
JS, et al. ACC/AHA guideline update for the management of patients with
unstable angina and non-ST-segment elevation myocardial infarction--
2002: summary article: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Committee
on the Management of Patients With Unstable Angina). Circulation. 2002;106
(14):1893-??1900, http://dx.doi.org/10.1161/01.CIR.0000037106.76139.53.
29. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the
developing world. Am Heart J. 2004;148(1):7-15, http://dx.doi.org/
10.1016/j.ahj.2003.11.027.
30. Kumar S, Kim CW, Simmons RD, Jo H. Role of Flow-Sensitive microRNAs
in Endothelial Dysfunction and Atherosclerosis: Mechanosensitive
Athero-miRs. Arterioscler Thromb Vasc Biol. 2014;34(10):2206-16, http://
dx.doi.org/10.1161/ATVBAHA.114.303425.
31. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes
J, et al. MicroRNA-126-5p promotes endothelial proliferation and limits
atherosclerosis by suppressing Dlk1. Nat Med. 2014;20(4):368-76, http://
dx.doi.org/10.1038/nm.3487.
32. Chen WJ, Zhang M, Zhao GJ, Fu Y, Zhang DW, Zhu HB, et al. MicroRNA-
33 in atherosclerosis etiology and pathophysiology. Atherosclerosis.
2013;227(2):201-8, http://dx.doi.org/10.1016/j.atherosclerosis.2012.11.025.
33. Wang H, Zhu HQ, Wang F, Zhou Q, Gui SY, Wang Y. MicroRNA-1 pre-
vents high-fat diet-induced endothelial permeability in apoE knock-out
mice. Mol Cell Biochem. 2013;378(1–2):153-9.
34. Muñoz-Pacheco P, Ortega-Hernández A, Miana M, Cachofeiro V,
Fernández-Cruz A, Gómez-Garre D. Ezetimibe inhibits PMA-
induced monocyte/macrophage differentiation by altering microRNA
expression: a novel anti-atherosclerotic mechanism. Pharmacol Res.
2012;66(6):536-43.
35. Gao S, Wassler M, Zhang L, Li Y, Wang J, Zhang Y, et al. MicroRNA-133a
regulates insulin-like growth factor-1 receptor expression and vascular
smooth muscle cell proliferation in murine atherosclerosis. Atherosclerosis.
2014;232(1):171-9, http://dx.doi.org/10.1016/j.atherosclerosis.2013.11.029.
36. Hsu A, Chen SJ, Chang YS, Chen HC, Chu PH. Systemic approach to
identify serum microRNAs as potential biomarkers for acute myocardial
infarction. Biomed Res Int. 2014;418628.
37. D’Alessandra Y, Carena MC, Spazzafumo L, Martinelli F, Bassetti B,
Devanna P, et al. Diagnostic potential of plasmatic MicroRNA signatures
in stable and unstable angina. PLoS One. 2013;8(11):e80345, http://dx.
doi.org/10.1371/journal.pone.0080345.
38. Wu C, Gong Y, Sun A, Zhang Y, Zhang C, Zhang W, et al. The human
MTHFR rs4846049 polymorphism increases coronary heart disease risk
through modifying miRNA binding. Nutr Metab Cardiovasc Dis. 2013;
23(7):693-8, http://dx.doi.org/10.1016/j.numecd.2012.02.009.
39. Jeon YJ, Kim OJ, Kim SY, Oh SH, Oh D, Kim OJ, et al. Association of the
miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic
stroke and silent brain infarction risk. Arterioscler Thromb Vasc Biol.
2013;33(2):420-30, http://dx.doi.org/10.1161/ATVBAHA.112.300251.
40. Palmieri D, Capponi S, Geroldi A, Mura M, Mandich P, Palombo D.
TNFa induces the expression of genes associated with endothelial
dysfunction through p38MAPK-mediated down-regulation of miR-149.
Biochem Biophys Res Commun. 2014;443(1):246-51, http://dx.doi.org/
10.1016/j.bbrc.2013.11.092.
41. Van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Mar-
shall WS, et al. Dysregulation of microRNAs after myocardial infarction
reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A.
2008;105(35):13027-32, http://dx.doi.org/10.1073/pnas.0805038105.
42. Zhao H, Wang J, Gao L, Wang R, Liu X, Gao Z, et al. MiRNA-424 protects
against permanent focal cerebral ischemia injury in mice involving sup-
pressing microglia activation. Stroke. 2013;44(6):1706-13, http://dx.doi.
org/10.1161/STROKEAHA.111.000504.
43. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA. An endo-
thelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in
pulmonary arterial hypertension. Nat Med. 2013;19(1):74-82.
44. Redell JB, Moore AN, Ward NH 3rd, Hergenroeder GW, Dash PK. Human
traumatic brain injury alters plasma microRNA levels. J Neurotrauma.
2010;27(12):2147-56, http://dx.doi.org/10.1089/neu.2010.1481.
263
CLINICS 2015;70(4):257-263 Circulating miRNAs and coronary artery disease
Md Sayed AS et al.
